The Parkinson's Progression Markers Initiative (PPMI) is a comprehensive clinical study launched in 2010 to identify biomarkers of Parkinson's Disease progression.[1] The study enrolls both individuals with Parkinson's Disease and healthy controls to identify objective markers that can track disease [1:1]
progression.[2] [2:1]
PPMI employs a multi-arm observational design with three main cohorts: [3]
PPMI has been instrumental in demonstrating that alpha-synuclein seeding activity in CSF can distinguish PD from healthy controls with high sensitivity and specificity.[20] [4:1]
Elevated neurofilament light chain (NfL) in CSF and blood correlates with more rapid disease progression in PD.[21] [5:1]
PPMI has identified that GBA mutations and LRRK2 variants influence disease progression and clinical phenotypes.[22] [6:1]
Individuals with RBD have a high likelihood of developing synucleinopathies, with conversion rates of 80-90% over 10-15 years.[23] [7:1]
PPMI data have enabled: [8:1]
PPMI involves over 50 clinical sites worldwide, including major research universities in North America, Europe, and Asia. [9:1]
All PPMI data are freely available to qualified researchers through the PPMI website, enabling global research collaboration.[28] [10:1]
PPMI continues to expand with: [11:1]
The study of Parkinson'S Progression Markers Initiative (Ppmi) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development. [12:1]
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions. [13:1]
Additional evidence sources: [14:1] [15:1] [16:1] [17:1] [18:1] [19:1] [20:1] [21:1] [22:1] [23:1] [24:1] [25:1] [26:1] [27:1] [28:1] [29:1] [30:1] [31:1] [32:1]
Marek K, et al. The Parkinson's Progression Markers Initiative. 2023. ↩︎ ↩︎
Parkinson Progression Marker Initiative. Baseline characteristics of the Parkinson's Progression Markers Initiative cohort. Neurology. 2014;83(5):394-405. 2014. ↩︎ ↩︎
Postuma RB, et al. The Montreal Cognitive Assessment: A screening tool for mild cognitive impairment in Parkinson's. 2015. ↩︎ ↩︎
Berg D, et al. Prodromal Parkinson's Disease: The decade ahead. 2014. ↩︎ ↩︎
Iranzo A, et al. REM sleep behavior disorder and prodromal neurodegeneration. 2013. ↩︎ ↩︎
Espay AJ, et al. Biomarkers in Parkinson's Disease. 2020. ↩︎ ↩︎
Fereshtehnejad SM, et al. New Parkinson's Disease subtypes. 2019. ↩︎ ↩︎
Lang AE, et al. Clinical trials in Parkinson's Disease. 2019. ↩︎ ↩︎
Goetz CG, et al. MDS-UPDRS: Movement Disorder Society Unified Parkinson's Disease Rating Scale. 2010. ↩︎ ↩︎
Nasreddine ZS, et al. The Montreal Cognitive Assessment (MoCA). 2005. ↩︎ ↩︎
Doty RL, et al. University of Pennsylvania Smell Identification Test (UPSIT). 1984. ↩︎ ↩︎
Stiasny-Kolster K, et al. REM sleep behavior disorder questionnaire. 2007. ↩︎ ↩︎
Singleton A, et al. Genetics in Parkinson's Disease. 2019. ↩︎ ↩︎
Mollenhauer B, et al. CSF biomarkers in Parkinson's Disease. 2011. ↩︎ ↩︎
Parnetti L, et al. Blood and CSF biomarkers in Parkinson's Disease. 2019. ↩︎ ↩︎
Benamer HT, et al. DaTscan SPECT in Parkinson's Disease. 2000. ↩︎ ↩︎
Pyatigorskaya N, et al. MRI biomarkers of Parkinson's Disease. 2020. ↩︎ ↩︎
Stoessl AJ. Dopamine transporter imaging in Parkinson's Disease. 2019. ↩︎ ↩︎
Singer W, et al. alpha-synuclein real-time quaking-induced conversion. 2022. ↩︎ ↩︎
Bacioglu M, et al. Neurofilament light chain in blood and CSF. 2016. ↩︎ ↩︎
Liu G, et al. GBA mutations in Parkinson's Disease. 2019. ↩︎ ↩︎
Postuma RB, et al. RBD and neurodegenerative disease. 2019. ↩︎ ↩︎
Cedarbaum JM, et al. Clinical trial design in Parkinson's Disease. 2018. ↩︎ ↩︎
Hauser RA, et al. Outcome measures in Parkinson's Disease clinical trials. 2020. ↩︎ ↩︎
Evans JR, et al. Clinical trials in Parkinson's Disease. 2016. ↩︎ ↩︎
PPMI Data Access Committee. PPMI data sharing policy. 2024. 2024. ↩︎ ↩︎
Heinzel S, et al. Update of the MDS research criteria for prodromal Parkinson's Disease. 2019. ↩︎ ↩︎
Chahine LM, et al. Digital biomarkers in Parkinson's Disease. 2020. ↩︎ ↩︎